α-Hederin has been found to reverse cisplatin resistance in NSCLC by silencing SLC7A11 and inhibiting miR-96-5p, activating DDIT3/ATF3-mediated ferroptosis [86]. This evidence concerns the gene ATF3 and non-small cell lung carcinoma.